Ashland (ASH) Q1 2026 earnings summary

Executive summary

• Q1 performance was steady with sales down 5% year-over-year to $386 million, supported by disciplined execution and cost actions amid ongoing demand softness in coatings and construction, and operational challenges including Calvert City outages and weather disruptions; net loss improved to $12 million from $165 million, driven by the absence of large impairment charges and improved operations.

• Life Sciences and Personal Care segments showed resilience, with Life Sciences achieving 4% sales growth and Personal Care maintaining stable demand despite the Avoca divestiture and isolated customer outages.

• Specialty Additives and Intermediates faced muted demand, especially in China and export markets, but cost actions and network benefits drove margin expansion in Specialty Additives.

• Early Q2 sales trends are encouraging, with improving momentum in December and January, and solid free cash flow despite temporary operational impacts.

• Exited the quarter with strong liquidity and expect continued progress on strategic priorities, supported by innovation and cost discipline.

Financial highlights

• Q1 sales were $386 million, down 5% year-over-year, mainly due to lower volume and the Avoca divestiture; excluding Avoca, sales declined 3%.

• Adjusted EBITDA was $58 million, down 5% year-over-year; margin held at 15%; excluding Avoca, Adjusted EBITDA declined 3%.

• Adjusted EPS (excluding intangible amortization) was $0.26, down 7% year-over-year; gross profit margin improved to 29.3%.

• Operating cash flow was $125 million, aided by a $103 million tax refund; free cash flow was $26 million, with nearly 50% conversion in a seasonally low quarter.

• Ended quarter with $900 million liquidity and net debt of $1.1 billion; net leverage at 2.7x.

Outlook and guidance

• Fiscal 2026 sales guidance narrowed to $1,835–$1,905 million; Adjusted EBITDA guidance narrowed to $400–$420 million, reflecting $11 million in temporary impacts from Calvert City startup delay and weather disruptions.

• Adjusted diluted EPS (excluding intangibles amortization) is projected to show double-digit growth; ongoing free cash flow conversion expected at ~50% of Adjusted EBITDA, with $100 million in capital expenditures.

• Life Sciences and Personal Care expected to remain resilient; Specialty Additives and Intermediates to see gradual, regionally uneven recovery.

• Second half-weighted performance expected, with cost savings and innovation driving margin improvement.